SCHEMBL4340484

SCHEMBL4340484

COc1ccc(C(O)(c2ccc(OC)cc2)[C@@H](Cc2ccccc2)NC(=O)CC(=O)N[C@H](Cc2ccccc2)C(O)(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.50
PPARG P37231 1/20 0.49
PPARA Q07869 1/20 0.49
FPR2 P25090 1/20 0.48
ALDH1A1 P00352 3/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
PLAU P00749 1/20 0.46
ELANE P08246 1/20 0.46
RAB9A P51151 2/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MMP1 P03956 4/20 0.46
MMP3 P08254 2/20 0.46
LDHA P00338 1/20 0.46
MMP2 P08253 1/20 0.46
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4342119 0.91 PPARG (0.50) CNR2PPARGPPARAFPR2ALDH1A1
SCHEMBL4337829 0.88 MMP1 (0.47) CNR2PPARGPPARAFPR2ALDH1A1
SCHEMBL4349557 0.86 KDM4E (0.50) ALDH1A1LMNARAB9ASMN1; SMN2CTRB1
SCHEMBL4342152 0.85 PSMB8 (0.47) CNR2KMT2AMEN1LMNARAB9A
SCHEMBL1152949 0.84 PPARG (0.44) CNR2PPARGPPARAFPR2ALDH1A1
SCHEMBL1154129 0.83 KMT2A (0.43) CNR2PPARGPPARAFPR2ALDH1A1
SCHEMBL1154001 0.83 KMT2A (0.43) CNR2PPARGPPARAFPR2ALDH1A1
SCHEMBL1153735 0.82 KMT2A (0.42) CNR2PPARGPPARAFPR2ALDH1A1
SCHEMBL4349008 0.81 ANPEP (0.44) ALDH1A1LMNAMAPTMMP1MMP3
SCHEMBL4337724 0.80 CTRB1 (0.45) PPARGFPR2ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612236-B2 Method for producing optically active bisamidoalcohol compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-03 US disclosed
US-20070100163-A1 Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced SUMITOMO CHEMICAL COMPANY, LIMITED 2007-05-03 US disclosed
EP-1698616-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND Sumitomo Chemical Company, Limited (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070100163-A1 Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced CCNL2, ARL1, ACSL3 CNR2 855/4885PPARG 2967/4885PPARA 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.